Monte Rosa Therapeutics, Inc.
GLUEHealthcareNASDAQBiotechnology · Last scanned Jul 16, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Monte Rosa Therapeutics, Inc. focuses on Biotechnology services and products. Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively. At a $1.98B market cap, Monte Rosa Therapeutics, Inc. ranks as a small-cap company within healthcare. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Market Cap
$1.98B
Beta
1.56
P/E (TTM)
—
P/E (Fwd)
-12.90
EPS (TTM)
$-1.48
EPS (Fwd)
$-1.81
ROE
-32.6%
ROA
-16.4%
Cash
$666.2M
Total Debt
$39.1M
Free CF
-$61.2M
52W Change
317.3%
Annual Financials
Cash vs Debt
Monte Rosa Therapeutics, Inc. holds $666.2M in cash against $39.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$61.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -32.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Monte Rosa Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing GLUE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.